SCHEDULE: Rosalind Entities Disclose 9.9% Stake in PolyPid Ltd.

Rosalind Advisors and affiliated entities report a 9.9% beneficial ownership in PolyPid Ltd., including shares and warrants, subject to a 9.99% ownership blocker.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 5,483,443 shares of PolyPid Ltd. common stock.
• This aggregate amount represents 9.9% of PolyPid Ltd.'s common stock, calculated based on 18,204,002 outstanding shares as of December 31, 2025.
• The reported beneficial ownership includes 696,556 shares of common stock and 4,786,887 shares that would be issuable upon the full conversion and exercise of warrants.
• A 'blocker provision' in the warrants prevents the holder from exercising them to the extent that beneficial ownership would exceed 9.99% of the common stock.
• Due to these blockers, the reporting persons were not able to exercise any of the warrants as of the filing date, meaning the actual number of shares of common stock beneficially owned, after giving effect to such blockers, is less than the aggregate reported amount.
• Rosalind Master Fund L.P. is deemed to beneficially own 696,556 shares of common stock, representing approximately 3.83% of the common stock, excluding the currently unexercisable warrant shares due to the blocker.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a standard beneficial ownership disclosure, providing transparency on a significant stake but not inherently positive or negative for the issuer's operational performance. The blocker provision adds a nuance regarding exercisable ownership.

Risks

• The blocker provision within the warrants limits the reporting persons' ability to exercise the 4,786,887 warrant shares if such exercise would result in beneficial ownership exceeding 9.99% of PolyPid Ltd.'s common stock, effectively preventing their exercise as of the filing date.

Industry Context

StockSavvy.ai notes that significant institutional ownership disclosures like this can signal investor confidence or strategic positioning in the biotech/pharma sector, especially for companies like PolyPid Ltd. which operates in drug development. Such filings provide transparency on major shareholder positions.

Stakeholder Impact

• Shareholders will be aware of a significant institutional holder, which could influence market perception regarding the company's investor base and potential future strategic moves.

Key Dates

Keywords

PolyPid, Rosalind Advisors, beneficial ownership, Schedule 13G, warrants, institutional ownership, M8001Q126